Patent ID: 8703799

Claim:
A method of treating a subject afflicted with an ailment selected from the group consisting of retinal disorders, neurofibromatoses, colon tumors, breast tumors, lung tumors, thyroid tumors, and glial tumors the method comprising: administering to the subject, for a time and in an amount sufficient to alleviate at least one symptom associated with the ailment, an NMDA receptor antagonist having a chemical structure selected from the group consisting of Structures A, B, and C, or an enantiomer, a racemic mixture of enantiomers, a non-racemic mixture of enantiomers, a diastereomer, or a mixture of diastereomers thereof, wherein R of Structure A is selected from the group consisting a hydroxyl group, an amino group, and a fluorine atom, provided that when R of Structure A is a fluorine atom, the antagonist is an enantiomer of Structure A, wherein R of Structures B and C is selected from the group consisting of a halo moiety, a nitrate group, a halomethyl group, a nitro moiety, an acyl moiety, a formyl moiety, an alkylsulfonyl moiety, an arylsulfonyl moiety, a cyano moiety, a hydroxyl group, and an amino group, and wherein one or more hydrogen atoms of the polycyclic ring of the antagonist are independently optionally replaced with a lower alkyl group.